<DOC>
	<DOCNO>NCT02304185</DOCNO>
	<brief_summary>The purpose study assess safety tolerability 2 different dose level trimeric glycoprotein140 ( gp140 ) administer 2-dosage regimen , intramuscularly ( injection substance muscle ) , without aluminum phosphate adjuvant healthy human immunodeficiency virus ( HIV ) -uninfected participant .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Study 2 Dose Levels Trimeric Glycoprotein140 ( gp140 ) Healthy Adult Volunteers</brief_title>
	<detailed_description>This single-center , randomize ( study drug assign chance ) , placebo-controlled ( study experimental treatment procedure compare pretend treatment drug test drug real effect ) , double-blind ( neither physician participant know treatment participant receives ) study . The study comprise Screening Period ( 4 week ) , Vaccination Period ( participant vaccinate Days 1 29 ) , Follow-up Period ( 48 week ) . All eligible participant randomly assign 1 2 sequential cohort ( low dose cohort high dose cohort ) . Participants low dose cohort receive 1 follow treatment : low dose ( 50 microgram [ mcg ] ) gp140 drug product ( DP ) , low dose gp140 DP adjuvant ( aluminum phosphate ) , placebo match low dose DP ; participant high dose cohort receive 1 follow treatment : high dose ( 250 mcg ) gp140 DP , high dose gp140 DP adjuvant , placebo match high dose DP . There interim safety review safety/tolerability low-dose cohort high-dose cohort receives study treatment . Total study duration 56 week per participant . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Participant must healthy basis physical examination , medical history , electrocardiogram ( ECG ) , laboratory criterion , vital sign measurement perform Screening Participants negative human immunodeficiency virus ( HIV ) infection Screening ( negative United States Food Drug Administrationapproved HIV diagnostic blood test ) All female participant childbearing potential must negative serum ( beta human chorionic gonadotropin ) Screening , negative urine pregnancy test predose Day 1 Day 29 A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction 3 month receive last dose study vaccine . A man must agree donate sperm 3 month receive last dose study vaccine Participants assess clinic staff low risk HIV infection Participant chronic active hepatitis B active hepatitis C , active syphilis infection , chlamydia , gonorrhea , trichomonas . Active syphilis document exam serology unless positive serology due past treated infection In 12 month prior enrollment , participant history newly acquire syphilis , gonorrhea , nongonococcal urethritis , herpes simplex virus type 2 ( HSV2 ) , chlamydia , pelvic inflammatory disease , trichomonas , mucopurulent cervicitis , epididymitis , proctitis , lymphogranulomavenereum , chancroid , hepatitis B Participant clinically significant acute chronic medical condition opinion Investigator would preclude participation ( example , history seizure disorder , bleeding/clotting disorder , autoimmune disease , active malignancy , poorly control asthma , active tuberculosis systemic infection ) Participant major surgery within 4 week prior study entry plan major surgery course study Participant thyroidectomy , thyroid disease require medication last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Acquired Immuno-Deficiency Syndrome</keyword>
	<keyword>Acquired Immunodeficiency Syndrome Virus</keyword>
	<keyword>Glycoprotein</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Placebo</keyword>
</DOC>